Looking for classes? Ksquare Career Institute, Bengaluru →
Human insulin is being commercially produced from a transgenic species of:
A
Rhizobium
B
Saccharomyces
C
Escherichia
D
Mycobacterium
Detailed Solution
Insulin consists of two short polypeptide chains, chain A and chain B, linked together by disulphide bridges.
In 1983, the American company Eli Lilly prepared two DNA sequences corresponding to the A and B chains of human insulin.
These sequences were introduced into the plasmids of Escherichia coli to produce the insulin chains.
Chains A and B were produced separately, extracted and combined by creating disulphide bonds to form human insulin (humulin).
Rhizobium is a nitrogen-fixing bacterium, Saccharomyces is yeast and Mycobacterium includes disease-causing bacteria; the classical commercial source described in NCERT is the transgenic bacterium Escherichia coli.
So human insulin is commercially produced from a transgenic species of Escherichia.
In 1983, the American company Eli Lilly prepared two DNA sequences corresponding to the A and B chains of human insulin.
These sequences were introduced into the plasmids of Escherichia coli to produce the insulin chains.
Chains A and B were produced separately, extracted and combined by creating disulphide bonds to form human insulin (humulin).
Rhizobium is a nitrogen-fixing bacterium, Saccharomyces is yeast and Mycobacterium includes disease-causing bacteria; the classical commercial source described in NCERT is the transgenic bacterium Escherichia coli.
So human insulin is commercially produced from a transgenic species of Escherichia.